Colorectal Cancer

Johanna Bendell, MD, discusses  the current and emerging treatment landscape of immunotherapy for patients with CRC.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses using immunotherapy for the treatment of patients with colorectal cancer.

Michael A. Morse, MD, recently discussed treatment decisions centered around the care of patients with metastatic colorectal cancer. Morse, professor of Medicine, Duke Cancer Institute, explained his treatment decisions in 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

The Therapeutic Management of Metastatic CRC

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the differences between right- and left-sided colon cancer.

In the phase III KEYNOTE-177 trial, investigators are hoping to show that frontline treatment with the PD-1 inhibitor pembrolizumab (Keytruda) can improve progression-free survival compared with standard-of-care chemotherapy in patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer.

Investigators aimed to evaluate the prognostic value of primary tumor location in patients with fully resected colon cancer, as well as its relationship to microsatellite instability-high (MSI-H), <em>RAS</em>, and <em>BRAF</em> mutational status, in a study presented at this year&#39;s World Congress on Gastrointestinal Cancer.

Heinz-Josef Lenz, MD, shares his excitement for&nbsp;findings from clinical studies on liquid biopsies, Immunoscore^&reg;, and primary tumor location in colorectal cancer.

Today, ABP-215, a biosimilar for bevacizumab developed by Amgen and Allergan, received FDA approval for the treatment of several different cancer types, making it the first biosimilar approved for the treatment of cancer.

Progression of Treatment in Colorectal Cancer

Manuel Hidalgo, MD, shares his insight on the growth of genetic testing in CRC.<br /> &nbsp;